113100-86-0

Basic information

• Product Name: methyl 4-(3-bromopropyl)benzoate
• Synonyms: methyl 4-(3-bromopropyl)benzoate;4-(3-bromopropyl)Benzoic acid methyl ester
• CAS NO: 113100-86-0
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12372
• Mol File: 113100-86-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 310.202°C at 760 mmHg
• Flash Point: 141.405°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 4-(3-bromopropyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(3-bromopropyl)benzoate(113100-86-0)
• EPA Substance Registry System: methyl 4-(3-bromopropyl)benzoate(113100-86-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 113100-86-0(Hazardous Substances Data)

Usage

General Description

Methyl 4-(3-bromopropyl)benzoate is an organic compound that belongs to the ester class of chemicals. Its chemical structure consists of a benzene ring with a methyl group and a 3-bromopropyl group attached to it. methyl 4-(3-bromopropyl)benzoate is commonly used in the production of perfumes, flavorings, and pharmaceuticals. It is also known for its use as an intermediate in the synthesis of other organic compounds. Additionally, it can be utilized as a solvent, and it exhibits moderate toxicity and irritation to the skin and eyes if not handled properly.

InChI:InChI=1/C11H13BrO2/c1-14-11(13)10-6-4-9(5-7-10)3-2-8-12/h4-7H,2-3,8H2,1H3

Upstream product

• 15403-22-2 4-(3-hydroxy-propyl)-benzoic acid methyl ester 
• 67-56-1 methanol 
• 6309-79-1 4-(3-Bromo-propyl)-benzoic acid 
• 81631-63-2 p-(methoxycarbonyl)-n-propylbenzene 
• 619-44-3 methyl 4-iodobenzoate 
• 41996-96-7 1-(4-acetylphenyl)-3-bromopropane 
• 637-59-2 1-Bromo-3-phenylpropane 
• 61266-36-2 methyl 4-(3-hydroxypropynyl)benzoate 
• 106-95-6 allyl bromide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 123876-53-9 4-(3-Bromopropyl)-benzoyl chloride 
• 1571-08-0 methyl 4-formylbenzoate 
• 73166-52-6 4-((E)-3-oxoprop-1-enyl)-benzoic acid methyl ester 

Downstream Products

• 160743-75-9 methyl 4-[3-(acetylthio)propyl]benzoate 
• 223577-14-8 4-(3-piperidin-1-yl-propyl)-benzoic acid methyl ester 
• 757965-95-0 4-[3-(2-hydroxymethyl-5-oxo-pyrrolidin-1-yl)-propyl]-benzoic acid methyl ester 
• 884490-85-1 4-(3-{2-oxo-5-[3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-propyl)-benzoic acid methyl ester 
• 223577-15-9 4-(3-piperidin-1-yl-propyl)-benzoic acid 
• 223577-17-1 [6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin-1-yl-propyl)-phenyl]-methanone 
• 160743-76-0 methyl 4-(3-thiopropyl)benzoate 
• 160743-78-2 4-(3-[(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl) benzoic acid 
• 160743-77-1 4-{3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]propyl}benzoic acid methyl ester 
• 160743-79-3 Diethyl N-[4-(3-[(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl)benzoyl]-S-glutamate 
• 431988-82-8 4-(3-{2-[3-(tert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-benzoic acid methyl ester 
• 6309-79-1 4-(3-Bromo-propyl)-benzoic acid 
• 123876-53-9 4-(3-Bromopropyl)-benzoyl chloride 
• 401928-16-3 3-[4-(3-(dibutylamino)propyl)benzoyl]-2-butyl-1-benzofuran-5-carboxylic acid 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

A nitric oxide donor nature of the benzofuran compounds (by machine translation)

The invention discloses a benzofuran compound with nitrous oxide donor property. The benzofuran compound is a compound shown by a general formula (I) or a pharmaceutically acceptable salt thereof, wherein in the formula, R1 or R2 represents independent hy

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.